COR Cencora Inc: רווח למניה ב-12 החודשים האחרונים

Cencora, Inc. (COR) dominates the oligopoly through its scale, although it is currently shifting its focus toward profitable biopharmaceutical consulting. The annual change in net income per share over a rolling period visualizes this trend, where 124.00 determines the current status of the parameter. Stringent regulatory control and complex logistics make it virtually impossible for new players to penetrate this sector.
AmerisourceBergen Corporation - פילוחים אנליטיים ומדדי מפתח (COR)

Cencora, Inc. (COR) represents a defensive asset with a high barrier to entry due to the complexity of its logistics networks. This metric captures the annual earnings per share (EPS) trend over a rolling period, neutralizing quarterly gaps. By analyzing the relative EPS YoY TTM growth rate on the GURU.Markets platform, an investor can observe the actual scaling efficiency despite low margins. The stability of the curve confirms the company's dominance in pharmaceutical distribution.